Visual pathway abnormalities Wilson's disease: an electrophysiological study using electroretinography and visual evoked potentials.
The pathogenesis of the pattern reversal visual evoked potential (PRVEP) abnormalities in patients with Wilson's disease (WD) has not been investigated earlier. Since electroretinography (ERG) assesses the functional integrity of the retina, it was used along with PRVEP to localize the abnormalities in PRVEP in Wilson's patients. Ten newly diagnosed Wilson's disease patients underwent PRVEP and flash ERG soon after the diagnosis was established. The PRVEP latencies were prolonged in comparison with the controls (P<0.001). Photopic and scotopic A waves and oscillatory potentials were prolonged (P<0. 02) with reduction in amplitudes of photopic A and B waves (P<0.001). Six of these patients were subjected to repeat PRVEP and flash ERG after the clinical improvement with specific therapy. Comparison of the pre and post-treatment visual electrophysiological studies revealed significant reduction in latencies of PRVEP and flash ERG A wave (P<0.05) with increase in amplitudes of P100 of PRVEP (P<0.05), A and B waves of flash ERG (P<0.01). These findings confirm the reported PRVEP changes in WD and in addition demonstrate the reversibility of the retinal dysfunction which partially contributes to the PRVEP abnormalities. To the best of our knowledge this is the first study of ERG in patients with Wilson's disease in the literature. Further, there have been no earlier reports in the literature evaluating the effect of specific treatment on the PRVEP and ERG in Wilson's disease.
Satishchandra
P
P
Department of Neurology, National Institute of Mental Health and Neuro Sciences (NIMHANS), 560 029, Bangalore, India. psatish@nimhans.kar.nio.in
Ravishankar Naik
K
K
D000293:Adolescent; D000328:Adult; D015913:Chelation Therapy; D002648:Child; D003300:Copper / Q000378:metabolism; D004359:Drug Therapy, Combination; D004596:Electroretinography / Q000187:drug effects; D005074:Evoked Potentials, Visual / Q000187:drug effects / Q000502:physiology*; D005260:Female; D006527:Hepatolenticular Degeneration / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D008297:Male; D010396:Penicillamine / Q000627:therapeutic use; D012160:Retina / Q000503:physiopathology; D013440:Sulfides / Q000627:therapeutic use; D014795:Visual Pathways / Q000503:physiopathology*; D019287:Zinc Sulfate / Q000627:therapeutic use
D013440:Sulfides; D019287:Zinc Sulfate; D003300:Copper; D010396:Penicillamine